Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Next Previous
X
Search
Trial Profile

A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zirconium silicate (Primary) ; Irbesartan; Lisinopril; Valsartan
  • Indications Hyperkalaemia; Renal failure
  • Focus Pharmacodynamics; Registrational
  • Acronyms STABILIZE-CKD
  • Sponsors AstraZeneca

    • Most Recent Events

    • 08 Mar 2024 This trial has been Discontinued in Italy (Global end date 30th Nov 23 )according to European Clinical trial database.
    • 07 Mar 2024 Status changed from active, no longer recruiting to discontinued.
    • 08 Jan 2024 Planned End Date changed from 19 Jan 2026 to 15 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top